Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18939268 | 0.85 | HCAR3 (0.43) | PKMSMN1; SMN2CNR2 | |
| SCHEMBL18939308 | 0.81 | KMT2A (0.46) | KMT2AFAAHALDH1A1MAPK1PDE7A | |
| SCHEMBL18939348 | 0.80 | KMT2A (0.45) | KMT2AFAAHALDH1A1MAPK1PDE7A | |
| SCHEMBL26643565 | 0.80 | KMT2A (0.45) | KMT2AFAAHALDH1A1MAPK1PDE7A | |
| SCHEMBL31389901 | 0.79 | KMT2A (0.46) | KMT2AFAAHALDH1A1MAPK1PDE7A | |
| SCHEMBL14357203 | 0.79 | PDE7A (0.45) | KMT2AFAAHALDH1A1MAPK1PDE7A | |
| SCHEMBL30979687 | 0.78 | FAAH (0.45) | KMT2AFAAHALDH1A1MAPK1PDE7A | |
| SCHEMBL4882370 | 0.77 | CNR2 (0.46) | CNR2 | |
| SCHEMBL16245033 | 0.76 | KMT2A (0.48) | KMT2AFAAHPOLBMAPT | |
| SCHEMBL20944275 | 0.75 | KMT2A (0.47) | KMT2AFAAHPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| US-10954247-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (NC) | 2021-03-23 | — | — | US | disclosed |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2021-03-11 | — | — | US | disclosed |
| EP-3386976-A1 | IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | Research Triangle Institute, International (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10100059-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180265518-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2018-09-20 | — | — | US | disclosed |
| WO-2017100558-A1 | IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | RESEARCH TRIANGLE INSTITUTE | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166577-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | KMT2A 4000/4885FAAH 473/4885ALDH1A1 3849/4885 |
| US-10100059-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | KMT2A 4000/4885FAAH 473/4885ALDH1A1 3849/4885 |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | KMT2A 4000/4885FAAH 473/4885ALDH1A1 3849/4885 |
| US-20210070767-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | KMT2A 4000/4885FAAH 473/4885ALDH1A1 3849/4885 |
| US-20180265518-A1 | APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF | APLNR, AP1G1, APMAP | KMT2A 4000/4885FAAH 473/4885ALDH1A1 3849/4885 |
| US-10954247-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | KMT2A 4000/4885FAAH 473/4885ALDH1A1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.